NYMIVI Trademark

Trademark Overview

On Tuesday, January 25, 2022, a trademark application was filed for NYMIVI with the United States Patent and Trademark Office. The USPTO has given the NYMIVI trademark a serial number of 97236483. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, July 15, 2024. This trademark is owned by Acasti Pharma US Inc.. The NYMIVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating subarachnoid hemorrhage
nymivi

General Information

Serial Number97236483
Word MarkNYMIVI
Filing DateTuesday, January 25, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, July 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for treating subarachnoid hemorrhage

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 7, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAcasti Pharma US Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540
Party NameAcasti Pharma US Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Brunswick, NJ 08902

Trademark Events

Event DateEvent Description
Friday, January 28, 2022NEW APPLICATION ENTERED
Friday, January 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 4, 2022ASSIGNED TO EXAMINER
Monday, November 7, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, November 7, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, November 7, 2022EXAMINERS AMENDMENT E-MAILED
Monday, November 7, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, November 7, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, February 7, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 7, 2023SOU EXTENSION 1 FILED
Tuesday, February 7, 2023SOU EXTENSION 1 GRANTED
Friday, December 29, 2023SOU EXTENSION 2 FILED
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 29, 2023SOU TEAS EXTENSION RECEIVED
Friday, December 29, 2023SOU EXTENSION 2 GRANTED
Monday, July 15, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 15, 2024SOU EXTENSION 3 FILED
Monday, July 15, 2024SOU EXTENSION 3 GRANTED
Friday, July 19, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, July 19, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 19, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

nymivi hemorrhage subarachnoid treating preparations pharmaceutical